Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cholecalciferol (Vitamin D3) in combination with artificial tears is being investigated by the University of Faisalabad for the treatment of non-Sjögren dry eye syndrome in patients with vitamin D deficiency. Cholecalciferol is a fat-soluble vitamin that, upon conversion to its active form calcitriol, binds to the Vitamin D receptor (VDR). This interaction is thought to exert anti-inflammatory and anti-oxidative effects, potentially improving tear film stability and reducing ocular surface inflammation. In this clinical context, an oral dose of 6000 IU/day is administered alongside conventional topical artificial tears to evaluate synergistic improvements in ocular parameters such as tear breakup time (TBUT) and Ocular Surface Disease Index (OSDI) scores.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cholecalciferol + artificial tears.